Chung-Han Lee

TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.

TL;DR: An analytic pipeline and visualization tool (metabolograms) is developed to bridge the gap between TCGA transcriptomic profiling and metabolomic data, which enables to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome.

TL;DR: Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types.

TL;DR: The mTOR pathway involves two functional complexes, TORC1 and TORC2, which have been defined by both their association with raptor or rictor, respectively, and their sensitivity to short-term rapamycin inhibition.

TL;DR: The coordinated relationship between mTOR and p53 during cellular stress provides a possible explanation for the benign nature of hamartoma syndromes, including TSC, and suggests that the efficacy of mTOR inhibitors in anti‐neoplastic therapy may also depend on p53 status, and m TOR inhibitors may antagonize the effects of genotoxic chemotherapeutics.